Floatz logo

.ALPHA.-TEA

Metastatic Carcinoma

Providence Health & ServicesSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

45 Active assets in the Metastatic Carcinoma cohort.

Asset / SponsorPhaseRating
TIPIRACIL
Academic and Community Cancer Research United
Phase 2B
Trifluridine
Academic and Community Cancer Research United
Phase 2B
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 1/2B
Palbociclib
Academic and Community Cancer Research United
Phase 2B
Binimetinib
Academic and Community Cancer Research United
Phase 2B

View all 50 →

Same molecule, other indications

.ALPHA.-TEA is also rated in:

sarcomaDormant
CC
Indicative ·
47 / 100
View asset →
lymphomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →